X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
https://www.onclive.com/view/trifluridine-tipiracil-plus-bevacizumab-provides-potential-first-line-alternative-to-bevacizumab-capecitabine-in-mcrc
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214008
https://www.globenewswire.com/news-release/2022/10/13/2534194/35550/en/XBiotech-Announces-First-Patient-Enrolled-into-the-French-National-Cancer-Institute-INCA-Sponsored-Phase-I-II-III-Clinical-Study-for-Natrunix-Therapy-for-Colorectal-Cancer.html
https://www.globenewswire.com/news-release/2022/04/28/2431533/35550/en/XBiotech-Announces-French-National-Agency-ANSM-Approval-and-National-Cancer-Institute-INSA-funding-to-Support-Phase-I-II-III-Clinical-Study-for-Natrunix-in-Combination-with-Triflur.html
https://www.indiainfoline.com/article/news-top-story/natco-pharma-launches-tipanat-tablets-for-advanced-colorectal-gastric-cancer-treatment-in-india-121111800397_1.html
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-lonsurf-207981-trifluridine-and-tipiracil-tablets-15-mg614-mg-and-20-mg819-mg-1574399890.pdf
https://www.prnewswire.com/news-releases/fda-approves-taiho-oncologys-lonsurf-trifluridinetipiracil-for-adult-patients-with-previously-treated-advanced-gastric-or-gastroesophageal-junction-gej-adenocarcinoma-300801154.html
https://www.businesswire.com/news/home/20190117005042/en/Servier-Taiho-Oncology-Present-Latest-LONSURF%C2%AE-trifluridinetipiracil
https://www.prnewswire.com/news-releases/taiho-oncology-and-servier-to-present-data-on-lonsurf-trifluridine-and-tipiracil-and-key-investigational-compound-tas-120-at-esmo-20th-world-congress-on-gastrointestinal-cancer-2018-300666547.html
https://www.prnewswire.com/news-releases/taiho-oncology-eliminates-co-pays-for-many-of-the-patients-treated-with-lonsurf-trifluridine-and-tipiracil-300661275.html
https://www.newswire.ca/news-releases/taiho-pharma-canada-inc-announces-health-canada-approval-of-lonsurf-trifluridine-and-tipiracil-tablets-for-metastatic-colorectal-cancer-675964673.html
https://www.pharmacompass.com/pdf/news/les-laboratoires-serviers-lonsurf-trifluridine-tipiracil-hydrochloride-receives-marketing-authorisation-in-eu-for-colorectal-neoplasms-1463138404.pdf
http://www.pharmatimes.com/Article/16-04-28/Servier_s_Lonsurf_approved_in_Europe_for_colorectal_cancer.aspx
http://www.prnewswire.com/news-releases/chmp-issues-positive-opinion-for-lonsurfr-trifluridinetipiracil-for-refractory-metastatic-colorectal-cancer-300227482.html
http://www.news-medical.net/news/20150615/Taiho-Servier-sign-exclusive-license-agreement-to-develop-and-commercialize-TAS-102-drug.aspx?utm_source=twitterfeed&utm_medium=twitter&utm_campaign=DTN+Pharma+News:
http://www.pharmatimes.com/Article/15-03-02/Taiho_submits_colorectal_cancer_drug_in_Europe.aspx
Market Place
Share 
